Celldex Therapeutics, Inc. – Product Pipeline Review – Q2 2011

Date: July 1, 2011
Pages: 69
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: CA334A033EDEN
Leaflet:

Download PDF Leaflet

Celldex Therapeutics, Inc. – Product Pipeline Review – Q2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Celldex Therapeutics, Inc. - Product Pipeline Review - Q2 2011” provides data on the Celldex Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Celldex Therapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Celldex Therapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Celldex Therapeutics, Inc. - Brief Celldex Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Celldex Therapeutics, Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Celldex Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Celldex Therapeutics, Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Celldex Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Celldex Therapeutics, Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Celldex Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Celldex Therapeutics, Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Celldex Therapeutics, Inc. and identify potential opportunities in those areas.
Celldex Therapeutics, Inc. Snapshot
Celldex Therapeutics, Inc. Overview
Key Information
Key Facts
Celldex Therapeutics, Inc. – Research and Development Overview
Key Therapeutic Areas
Celldex Therapeutics, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Celldex Therapeutics, Inc. – Pipeline Products Glance
Celldex Therapeutics, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Celldex Therapeutics, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Celldex Therapeutics, Inc. – Drug Profiles
CDX-011
  Product Description
  Mechanism of Action
  R&D Progress
CDX-1135
  Product Description
  Mechanism of Action
  R&D Progress
CDX-1307
  Product Description
  Mechanism of Action
  R&D Progress
CDX-1307 Vaccine Regimen + Gemcitabine + Cisplatin
  Product Description
  Mechanism of Action
  R&D Progress
CDX-1401 + Resiquimod
  Product Description
  Mechanism of Action
  R&D Progress
Rindopepimut
  Product Description
  Mechanism of Action
  R&D Progress
Ty800
  Product Description
  Mechanism of Action
  R&D Progress
Velafermin
  Product Description
  Mechanism of Action
  R&D Progress
Ciprofloxacin + Peru-15-pCTB
  Product Description
  Mechanism of Action
  R&D Progress
DCVax-001
  Product Description
  Mechanism of Action
  R&D Progress
CDX-014
  Product Description
  Mechanism of Action
  R&D Progress
CDX-1127
  Product Description
  Mechanism of Action
  R&D Progress
CDX-1189
  Product Description
  Mechanism of Action
  R&D Progress
Mobista
  Product Description
  Mechanism of Action
  R&D Progress
Celldex Therapeutics, Inc. – Pipeline Analysis
Celldex Therapeutics, Inc. – Pipeline Products by Therapeutic Class
Celldex Therapeutics, Inc. - Pipeline Products By Target
Celldex Therapeutics, Inc. – Pipeline Products by Route of Administration
Celldex Therapeutics, Inc. – Pipeline Products by Molecule Type
Celldex Therapeutics, Inc. – Recent Pipeline Updates
Celldex Therapeutics, Inc. - Dormant Projects
Celldex Therapeutics, Inc. – Company Statement
Celldex Therapeutics, Inc. – Locations And Subsidiaries
Head Office
Financial Deals Landscape
Celldex Therapeutics, Inc., Deals Volume Summary, 2004 to YTD 2011
Celldex Therapeutics, Inc., Deals Summary By Region, 2004 to YTD 2011
Celldex Therapeutics, Inc., Deals Summary, 2004 to YTD 2011
Celldex Therapeutics, Inc. Detailed Deal Summary
Asset Purchase
Celldex Therapeutics Acquires Rights To Immune Stimulatory Molecules From Amgen
Merger
AVANT Immunotherapeutics Merges With Celldex Therapeutics
Acquisition
Celldex Therapeutics Completes Acquisition Of CuraGen
Equity Offering
AVANT Immunotherapeutics Completes Private Placement Of $24.65 Million
AVANT Immunotherapeutics Enters Into Research Agreement With Select Vaccines
Celldex Therapeutics Terminates Co-Development Agreement With Select Vaccines
Licensing Agreements
Celldex Therapeutics Enters Into An Agreement With Vaccine Technologies
Celldex Enters Into An Agreement With University of Southampton
Celldex Therapeutics Enters Into A Licensing Agreement With 3M Company
Celldex Therapeutics Enters Into License And Development Agreement With Pfizer
Celldex Therapeutics Enters Into Licensing Agreement With Ludwig Institute
Celldex Therapeutics Enters Into Licensing Agreement With Duke University
Celldex Therapeutics Enters Into Licensing Agreement With The Rockefeller University
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 69

LIST OF TABLES

Celldex Therapeutics, Inc. – Pipeline by Therapy Area and Indication, 2011
Celldex Therapeutics, Inc. – Pipeline by Stage of Development, 2011
Celldex Therapeutics, Inc. – Monotherapy Products in Pipeline, 2011
Celldex Therapeutics, Inc. – Combination Treatment Modalities in Pipeline, 2011
Celldex Therapeutics, Inc. - Phase II, 2011
Celldex Therapeutics, Inc. - Phase I, 2011
Celldex Therapeutics, Inc. - Pipeline By Therapeutic Class, 2011
Celldex Therapeutics, Inc. - Pipeline By Target, 2011
Celldex Therapeutics, Inc. – Pipeline By Route of Administration, 2011
Celldex Therapeutics, Inc. – Pipeline By Molecule Type, 2011
Celldex Therapeutics, Inc. – Recent Pipeline Updates, 2011
Celldex Therapeutics, Inc. - Dormant Developmental Projects, 2010
Celldex Therapeutics, Inc., Deals Summary, 2004 to YTD 2011
Celldex Therapeutics, Inc., Deals Summary by Region, 2004 to YTD 2011
Celldex Therapeutics, Inc., Deals Summary, 2004 to YTD 2011 46

LIST OF FIGURES

Celldex Therapeutics, Inc. – Pipeline by Therapy Area and Indication, 2011
Celldex Therapeutics, Inc. – Pipeline by Stage of Development, 2011
Celldex Therapeutics, Inc. – Monotherapy Products in Pipeline, 2011
Celldex Therapeutics, Inc. – Combination Treatment Modalities in Pipeline, 2011
Celldex Therapeutics, Inc. – Pipeline By Therapeutic Class, 2011
Celldex Therapeutics, Inc. - Pipeline By Target, 2011
Celldex Therapeutics, Inc. – Pipeline By Route of Administration, 2011
Celldex Therapeutics, Inc. – Pipeline By Molecule Type, 2011 36

Ask Your Question

Celldex Therapeutics, Inc. – Product Pipeline Review – Q2 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: